Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9CEI5)

• Drug Name: Bevacizumab + Trastuzumab Drug Info
• Synonyms: Lithocholic acid; LITHOCHOLIC ACID; 434-13-9; Lithocolic acid; Lithocholate; 3alpha-Hydroxy-5beta-cholanic acid; 3alpha-Hydroxy-5beta-cholan-24-oic acid; 3-Hydroxycholan-24-oic acid; 3alpha-Hydroxycholanic acid; 3-alpha-Hydroxycholanic acid; 5beta-Cholanic acid-3alpha-ol; NCI-C03861; 3alpha-Hydroxy-5beta-cholanoic acid; (3alpha,5beta)-3-hydroxycholan-24-oic acid; 3-alpha-Hydroxy-5-beta-cholanic acid; CCRIS 363; UNII-5QU0I8393U; 3alpha-Hydroxy-5beta-cholanate; 5-beta-Cholanic acid, 3-alpha-hydroxy-; Cholan-24-oic acid, 3-hydroxy-,

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9903
  CAS Number: CAS 434-13-9
  TTD Drug ID: DM9CEI5
  VARIDT Drug ID: DR00639

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[4]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[5]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[6]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[7]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[8]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[9]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[10]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[11]
Pertuzumab	DMHJV0X	Breast cancer	2C60-2C65	Approved	[2]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[12]

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Metastatic colorectal cancer	2B91	Approved	[13]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[14]
Ranibizumab	DMSYPNW	Hereditary hemorrhagic telangiectasia	LA90.00	Approved	[15]
Bevacizumab	DMSD1UN	Metastatic colorectal cancer	2B91	Approved	[16]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[17]
Bevacizumab + Rituximab	DM9EXGI	Lymphoma	2A80-2A86	Phase 3	[2]
Bevacizumab + Erlotinib	DM0MI81	Metastatic colorectal cancer	2B91	Phase 3	[2]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Phase 3	[18]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[19]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[20]

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[3]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[21]
Obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[22]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[23]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[24]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[25]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[26]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[27]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[28]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[2]
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Antagonist	[3]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[2]

References

• [1] AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25.
• [2] Clinical pipeline report, company report or official report of Roche (2009).
• [3] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [4] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [6] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [8] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [15] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [16] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [17] Clinical pipeline report, company report or official report of Genentech (2009).
• [18] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [19] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [20] Bispecific antibodies and their applications
• [21] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [22] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [23] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [24] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [25] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [26] Clinical pipeline report, company report or official report of ENYO Pharma.
• [27] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [28] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [29] Clinical pipeline report, company report or official report of Metacrine.